Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||LY3127804 + Ramucirumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LY3127804||LY3127804 is an antibody that targets Angiopoietin-2 (Ang2), resulting in reduced angiogenesis, and potentially resulting in decreased tumor growth in combination with other agents (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3259, PMID: 32741971).|
|Ramucirumab||Cyramza||LY3009806||VEGFR2 Antibody 4||Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (PMID: 24094768). Cyramza (ramucirumab) is FDA approved for use as a monotherapy or in combination with paclitaxel in patients with gastric or gastroesophageal junction adenocarcinoma who progressed on chemotherapy, in combination with erlotinib as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations or L858R, in combination with decetaxel in patients with NSCLC who progressed on prior therapy, in combination with FOLFIRI in patients with colorectal cancer who progressed on prior therapy, and as monotherapy in patients with hepatocellular carcinoma who have received sorafenib (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||LY3127804 + Ramucirumab||Phase I||Actionable||In a Phase I trial, the combination treatment of LY3127804 and Cyramza (ramucirumab) at various doses in advanced solid tumor patients demonstrated safety and was well-tolerated, and led to a best overall response of partial responses observed in four patients, including one each with clear cell endometrial carcinoma, cervix squamous cell carcinoma, carcinoma of unknown primary, and gastroesophageal junction adenocarcinoma, and resulted in stable disease in 37% (13/35) (PMID: 32741971; NCT02597036).||32741971|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|